Biosortia exists because the most important small-molecule signals in biology are not sitting in ordinary screening libraries. They are hidden in living microbial communities, shaped by evolution, and largely inaccessible to conventional discovery.
Our mission, vision, and discovery philosophy begin with a simple belief: if we can recover and decode nature’s hidden signaling chemistry at scale, we can change where the next generation of therapeutic pipelines comes from.
Drug discovery has spent decades expanding synthetic chemical space. Biosortia is expanding biological access — recovering molecules that living systems have already used, tested, selected, and refined.
Microbial small molecules are shaped by ecological pressure, biological necessity, and chemical communication.
Industrial-Scale Microbiome Mining opens chemical space that small samples and culturing cannot reliably access.
BiosortAI is most powerful when trained and guided by molecules, spectra, habitats, genomics, and activity from living systems.
Evolutionarily informed starting points may improve prioritization, derisking, and translational logic before formal development.
Biosortia’s mission is to make previously inaccessible microbiome-derived small molecules available for discovery, understanding, and development. Through Industrial-Scale Microbiome Mining, proprietary datasets, and BiosortAI, we transform hidden cellular signals into therapeutic starting points, diagnostic hypotheses, AI-ready data, and patentable pipeline opportunities.
Biosortia envisions a world where microbiome-derived chemistry becomes a foundational source of new medicines, diagnostics, and biological insight — and where the dark matter of microbial signaling becomes searchable, understandable, developable, and valuable.
Click each principle to see how it changes the way Biosortia thinks about discovery.
Select a principle to explore Biosortia’s discovery philosophy.
Biosortia is not simply another AI drug discovery company or another microbiome company.
Begin with large libraries, computational guesses, and broad screening campaigns, often far from biological context.
Begin with molecules already shaped inside living microbial systems.
Low-abundance microbial molecules remain invisible, unobtainable, or too dilute for research use.
Use industrial-scale access to concentrate and recover hidden molecular signals.
AI systems are only as valuable as the data and biological priors that train and constrain them.
Use BiosortAI with proprietary molecules, spectra, habitats, activity data, and genomic context.
A visual companion to the strategic shift from generic chemical screening toward biology-grounded discovery.
Watch directly on YouTube →This section distills Biosortia’s draft Eroom’s Law framework into plain language for investors, pharma, biotech, and researchers.
Modern drug discovery has expanded screening, synthetic chemistry, computation, and AI — yet productivity has continued to decline. Biosortia’s view is that the problem is not simply a lack of molecules, but a lack of biologically meaningful starting points.
Synthetic chemical space expands almost without limit, but the fraction of molecules that satisfy efficacy, selectivity, safety, and ADME constraints can become increasingly diluted. Natural systems offer finite but biologically shaped priors — molecules and patterns already selected inside living systems.
Microbiome-derived molecules may carry useful information from living systems before a synthetic program even begins.
The goal is not only to generate or screen more molecules. The goal is to find more meaningful candidates per unit of effort.
Biosortia’s approach combines natural-prior discovery, BiosortAI prioritization, and synthetic or derivative exploration.
Biosortia’s draft framework links declining R&D productivity to natural-product saturation, synthetic-space dilution, and the need for hybrid discovery strategies that use natural priors to improve AI and synthetic search.
These principles are designed to guide science, BD, IP, partnerships, and pipeline decisions.
Reveal the opportunity, not the map. Public pages should invite engagement while keeping structures, exact masses, habitats, and search logic controlled.
Start with biological logic, then push toward wet validation, safety, PK, analytical confirmation, and partner diligence.
Microbiome-derived molecules may offer better starting points because they originate from systems that already use chemical signaling.
Every discovery can strengthen datasets, IP, AI models, internal pipeline value, and future partner projects.
This section quietly routes each audience without copying the partnering page.
Metabolic disease, gut-brain signaling, mucosal immunology, diagnostics, and enabling technologies.
View PipelinePartners can bring targets, phenotypes, assays, unknown molecules, or desired activities.
Explore BiosortAIDeep microbial molecule datasets, spectral features, genomic context, and activity-linked hypotheses.
Discuss DataPatentable molecule families, derivatives, diagnostics, methods, and enabling technologies.
Start ConversationThe company’s mission and vision are rooted in access: access to hidden molecules, hidden signaling logic, hidden datasets, and hidden therapeutic starting points that could reshape how pipelines are created.
“Within ten years, most therapeutic pipelines will trace back to the untapped chemistry of the microbiome. Biosortia is building that future today.”